BILLERICA, Mass., Nov. 2, 2016 /PRNewswire/ -- Bruker today
announced a technology acquisition in support of its
microbiology business and its world-leading MALDI
Biotyper microbial identification platform. Financial
details were not disclosed.
Bruker has acquired selected assets in Glasgow, UK for the development, validation
and commercialization of molecular assays for applications in
microbiology. Bruker has acquired laboratory infrastructure
and IP in the NAT assay field, including real-time PCR assays for
microbiology. In parallel, Bruker has hired an experienced
R&D, operations and commercial team in Glasgow to drive PCR-based syndromic panel
development for Bruker's MALDI Biotyper platform.
The MALDI Biotyper offers fast, highly accurate
and cost-efficient microbial identification with exceptionally
broad species coverage, based on proteomic fingerprinting.
Molecular multiplex and syndromic panel testing is another growing
field in clinical microbiology. When a rapid, targeted answer
is required without prior microbial cultivation, multiplex PCR
assays for the identification of selected bacterial, fungal and
viral species, and for the fast detection of resistance genes, are
highly complementary to broad-coverage, untargeted proteomic
identification from isolates after overnight culture. Such
proteomic assays and NAT assays are expected to be both performed
on the same MALDI Biotyper platform.
Applications for targeted multiplex PCR assays arise in early
screening, confirmation testing and broader syndromic testing.
Dr. Wolfgang Pusch, Executive
Vice President for Clinical MALDI Solutions at Bruker Daltonics,
commented: "In addition to conventional, targeted real-time
PCR assays, Bruker sees further advantages in combining multiplexed
syndromic PCR assays with a read-out on the MALDI
Biotyper platform. Bruker intends to validate and
launch the real-time PCR assays which have been acquired, and
develop new multiplex PCR panels on the MALDI
Biotyper platform in order to expand its assay menu to
rapid targeted bacterial, fungal and viral identification, to fast
antibiotic resistance testing, as well as to syndromic
panels. With over 2,000 MALDI Biotypers already
installed worldwide for fast, highly accurate and untargeted
microbial identification, we are excited to bring new NAT multiplex
assay and syndromic panel capabilities to our customers over
time."
About the Bruker MALDI Biotyper
The MALDI Biotyper family of systems enables
molecular identification, and taxonomical classification or
de-replication of microorganisms like bacteria, yeasts and
fungi. Classification and identification of microorganisms is
achieved reliably and quickly using proteomic fingerprinting by
high-throughput MALDI-TOF mass spectrometry. The MALDI
Biotyper uses proteomic fingerprints from bacterial strains
for identification. Published studies have highlighted the
greater accuracy, broader coverage and lower cost offered, as well
as faster time-to-result (TTR).
Applications of the MALDI Biotyper platform
include clinical routine microbial identification, environmental
and pharmaceutical analysis, taxonomical research, food and
consumer product safety and quality control, as well as marine
microbiology. In many European and international laboratories
the MALDI Biotyper has replaced classical biochemical
testing for bacterial identification due to its accuracy, speed,
extensive species coverage, ease of use and cost
effectiveness. Classical biochemical techniques detect
different metabolic properties of microorganisms, can take many
hours or even days for completion, and often lack
specificity.
The robust MALDI Biotyper workflow requires
minimal sample preparation and offers low consumables cost.
The products of the MALDI Biotyper family are
available in a research-use-only (RUO) version, as the U.S.
FDA-cleared MALDI Biotyper CA System, or in an IVD-CE
version according to EU directive EC/98/79. The MALDI
Biotyper also has medical device registrations in numerous
other countries. RUO versions of the MALDI
Biotyper allow selected high-value antimicrobial resistance
tests in translational research, and subtyping
capabilities.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical and
diagnostic solutions enable customers to explore life and materials
at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Investor Contact:
Miroslava
Minkova
Head of Investor Relations
T: +1 (978) 663–3660, ext. 1479
E: miroslava.minkova@bruker.com
Media Contact:
Dr. Winfried
Busch
Bruker Daltonics Microbiology Business
Tel: +49-421-2205-1242
E: Winfried.Busch@bruker.com
Logo -
http://photos.prnewswire.com/prnh/20160411/353805LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-nucleic-acid-testing-nat-assays-and-syndromic-panel-technology-to-expand-its-maldi-biotyper-platform-300356059.html
SOURCE Bruker Corporation